23andMe Holding EPS - Earnings per Share 2021-2024 | MEHCQ
23andMe Holding eps - earnings per share from 2021 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| 23andMe Holding Annual EPS |
| 2024 |
$-28.00 |
| 2023 |
$-13.80 |
| 2022 |
$-12.00 |
| 2021 |
$-36.80 |
| 2020 |
$-81.00 |
| 2020 |
$-56.80 |
| 23andMe Holding Quarterly EPS |
| 2024-12-31 |
$-2.01 |
| 2024-09-30 |
$-2.32 |
| 2024-06-30 |
$-2.80 |
| 2024-03-31 |
$-8.67 |
| 2023-12-31 |
$-11.56 |
| 2023-09-30 |
$-3.17 |
| 2023-06-30 |
$-4.60 |
| 2023-03-31 |
$-2.80 |
| 2022-12-31 |
$-4.00 |
| 2022-09-30 |
$-3.00 |
| 2022-06-30 |
$-4.00 |
| 2022-03-31 |
$-2.00 |
| 2021-12-31 |
$-4.20 |
| 2021-09-30 |
$-0.80 |
| 2021-06-30 |
$-5.00 |
| 2021-03-31 |
$36.60 |
| 2020-12-31 |
$-9.20 |
| 2020-09-30 |
$-7.60 |
| 2020-06-30 |
$-7.60 |
| 2020-03-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.220B |
|
23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.
|
